Terms: = Ovarian cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
3803 results:
1. Comparative Analysis of Primary ovarian cancer Cells and Established Cell Lines as a New Tool for Studies on ovarian cancer Cell Complexity.
Szyposzynska A; Bielawska-Pohl A; Paprocka M; Bar J; Murawski M; Klimczak A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791431
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Bioinformatic Investigation of tp53 Dysregulation in Diverse cancer Landscapes.
Khan R; Pari B; Puszynski K
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790205
[TBL] [Abstract] [Full Text] [Related]
3. Mucinous cystadenoma and benign mesonephric-like proliferation in the ovary - Further evidence for clonal relationship.
Hiller GGR; Höhn AK; Krücken I; Monecke A; Reske D; Brambs CE; Horn LC
Pathol Res Pract; 2024 Jun; 258():155336. PubMed ID: 38723326
[TBL] [Abstract] [Full Text] [Related]
4. Pan-cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
[TBL] [Abstract] [Full Text] [Related]
5. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
7. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast cancer-Associated Germline Pathogenic Variants in Mexico.
Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
[TBL] [Abstract] [Full Text] [Related]
8. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
9. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
10. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
11. Harmaline induces apoptosis and inhibits migration in A2780 ovarian cancer cells in vitro.
Shariat Razavi SA; Taghdisi Khaboushan M; Jafari R; Shahini A; Ferns GA; Bahrami A
Physiol Rep; 2024 Mar; 12(6):e15984. PubMed ID: 38531560
[TBL] [Abstract] [Full Text] [Related]
12. CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell.
Moradi Z; Kazemi M; Jamshidi-Khalifelou R; Bahramnia V; Esfandmaz F; Rahnavard R; Moradgholi B; Piri-Gharaghie T
Funct Integr Genomics; 2024 Mar; 24(2):61. PubMed ID: 38507114
[TBL] [Abstract] [Full Text] [Related]
13. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.
de Freitas Ribeiro AA; Junior NMC; Dos Santos LL
Eur J Med Res; 2024 Mar; 29(1):187. PubMed ID: 38504328
[TBL] [Abstract] [Full Text] [Related]
14. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract] [Full Text] [Related]
15. Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines.
Zafari J; Rastegar-Pouyani N; Javani Jouni F; Najjar N; Azarshin SZ; Jafarzadeh E; Abdolmaleki P; Hoseini Shirazi F
Sci Rep; 2024 Mar; 14(1):5792. PubMed ID: 38461218
[TBL] [Abstract] [Full Text] [Related]
16. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of tp53 mutations with platinum resistance when combined with gene expression.
Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
[TBL] [Abstract] [Full Text] [Related]
17. STEAP3 Affects ovarian cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway.
Han Y; Fu L; Kong Y; Jiang C; Huang L; Zhang H
Mediators Inflamm; 2024; 2024():4048527. PubMed ID: 38440354
[TBL] [Abstract] [Full Text] [Related]
18. HER2-low and Overexpression in Mucinous ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
[TBL] [Abstract] [Full Text] [Related]
19. cancer Risks Associated With
Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
[TBL] [Abstract] [Full Text] [Related]
20. Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands.
Teixeira RG; Stefanelli A; Pilon A; Warmers R; Fontrodona X; Romero I; Costa PJ; Villa de Brito MJ; Hudec X; Pirker C; Türck S; Antunes AMM; Kowol CR; Ott I; Brozovic A; Sombke A; Eckhard M; Tomaz AI; Heffeter P; Valente A
J Med Chem; 2024 Apr; 67(8):6081-6098. PubMed ID: 38401050
[TBL] [Abstract] [Full Text] [Related]
[Next]
